These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Cytokines other than growth factors in bone marrow transplantation. Ferrara JL Curr Opin Oncol; 1994 Mar; 6(2):127-34. PubMed ID: 7516711 [TBL] [Abstract][Full Text] [Related]
31. An epithelial target site in experimental graft-versus-host disease and cytokine-mediated cytotoxicity is defined by cytokeratin 15 expression. Whitaker-Menezes D; Jones SC; Friedman TM; Korngold R; Murphy GF Biol Blood Marrow Transplant; 2003 Sep; 9(9):559-70. PubMed ID: 14506658 [TBL] [Abstract][Full Text] [Related]
32. Cytokine inhibitors and graft-versus-host disease. Ferrara JL Ann N Y Acad Sci; 1995 Dec; 770():227-36. PubMed ID: 8597363 [TBL] [Abstract][Full Text] [Related]
33. Why is graft-versus-host disease sometimes associated with leukoderma and fewer melanocytic naevi? Feily A; Namazi MR J Cosmet Dermatol; 2010 Mar; 9(1):64-5. PubMed ID: 20367675 [No Abstract] [Full Text] [Related]
34. Xenoreactivity in mouse + rat-->mouse chimeras. Conrad BG; Wren SM; Thai NL; Wang SC; Ricordi C; Fung JJ; Perry FE; Ildstad ST Transplant Proc; 1993 Feb; 25(1 Pt 1):455-6. PubMed ID: 8438377 [No Abstract] [Full Text] [Related]
35. [Capacity of regenerated spleen cells to accomplish a graft-versus-host reaction]. Kharlova GV; Bliakher MS; Gambarov SS Biull Eksp Biol Med; 1976 Mar; 81(3):373-4. PubMed ID: 8175 [No Abstract] [Full Text] [Related]
36. Effects of interleukin 2 on leukemia development after bone marrow transplantation in AKR/J mice. Hashino S; Imamura M; Zhu X; Imai K; Kobayashi S; Tanaka J; Fujii Y; Kasai M; Miyazaki T Transplantation; 1995 Jun; 59(11):1642-5. PubMed ID: 7778185 [No Abstract] [Full Text] [Related]